Craft

Opthea

Stock Price

$0.9

2024-10-04

Market Capitalization

$1 B

2024-10-04

Revenue

$25 K

FY, 2025

Opthea Summary

Company Summary

Overview
Opthea (formerly Circadian Technologies) is a biopharmaceutical company developing a therapy for the treatment of retinal diseases. Its technology blocks two members of the vascular endothelial growth factor family that cause blood vessels to grow and leak.
Type
Public
Status
Active
Founded
2012
HQ
South Yarra, AU | view all locations
Website
https://www.opthea.com/
Cybersecurity rating
ESG rating
30-39 out of 100|View all ESG data
Sectors

Key People

  • Megan Baldwin

    Megan Baldwin, Chief Executive Officer & Managing Director

  • Annette Leahy

    Annette Leahy, Director, Clinical Research

  • Ian Leitch

    Ian Leitch, Director of Clinical Research

  • Jeremy Levin

Operating MetricsView all

Phase I Trials Products

100.0%

FY, 2020

Phase II Trials Products

2
100.0%

FY, 2020

LocationsView all

2 locations detected

  • South Yarra, VIC HQ

    Australia

    suite 0403, level 4/650 Chapel St

  • Toorak, VIC

    Australia

    Level 1/10 Wallace Ave

Opthea Financials

Summary Financials

Revenue (H1, 2026)
$1.0K
Gross profit (H1, 2026)
$357.1M
Net income (H1, 2026)
$339.9M
Cash (H1, 2026)
$33.2M
EBIT (H1, 2026)
$350.1M

Footer menu